CONNECTIVE TISSUE DISEASE-ASSOCIATED THROMBOCYTOPENIA
Clinical trials for CONNECTIVE TISSUE DISEASE-ASSOCIATED THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new CONNECTIVE TISSUE DISEASE-ASSOCIATED THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for CONNECTIVE TISSUE DISEASE-ASSOCIATED THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that cause autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment is given as a one-time infusion and aims…
Matched conditions: CONNECTIVE TISSUE DISEASE-ASSOCIATED THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 08:42 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a universal CAR T-cell therapy designed to target and destroy certain immune cells (those with CD19 or BCMA markers) that drive autoimmune diseases. It enrolls 12 adults with severe conditions like lupus, scleroderma, or vasculitis that have not respo…
Matched conditions: CONNECTIVE TISSUE DISEASE-ASSOCIATED THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 22, 2026 13:52 UTC